JDC Clinical Research Unit
JDC Clinical Research Unit showcases favorable research environment for the research participants in patient-oriented studies. Volunteer participants are the asset of JDC's research oriented efforts, contributing to breakthroughs in the field of diabetes.
Search for us at:
JDC aim for furtherance of the modern technologies in diabetes, not only for this generation, but also for the heirs to board......
Contribution to medical advancements through research is always a great matter of concern. Perhaps, there may be many who have a personal choice of volunteering in clinical trials but haven't got a chance yet. JDC offers great opportunity and maximum credibility for you to be part of diabetes research.
If you are interested to take part in one of the path breaking clinical trials in diabetes, please ask your doctor at JDC or enquire with Research Team of Jothydev's Diabetes Research Centre at +919495346200 or email us at email@example.com
You may participate in any of these following ongoing clinical trials :-
JDC/GT/022/2020 (NCT 04214704) (Genteel)
Open center, 24- week, cross over trial to assess the benefits of a painless lancing device among diabetes subjects in improving self-monitoring frequency and HbA1c.
A randomised, double-blind, parallel-group, placebo-controlled trial comparing oral semaglutide verses placebo both administered once daily and added to standard of care in patients aged≥50 with type two diabetes at high risk of cardiovascular events.
A prospective, multi-centric, open label, single-arm, phase 4 study to evaluate the safety and efficacy of canagliflozin+ metformin hydrochloride IR fixed-dose combination as an adjunct to diet and exercise to improve glycemic control in Indian adult patients with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate.
NN9924-4437 (PIONEER TEENS)
Efficacy and safety of oral semaglutide versus placebo, both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes- a randomised, double-blind, placebo-controlled, parallel-group, multi-national, and multicentre clinical trial that includes a 52-week treatment period followed by a 12-week off-trial product follow-up period.
NN1436-4625 (ONWARDS 6)
A 26-week, randomised multicenter, open label, active -controlled, parallel group two armed, treat to -target trial investigating the effect on glycaemic control and safety of treatment with once weekly insulin icodec compared to once daily insulin degludec both in combination with insulin aspart in adults with type 1 diabetes, with a 26-week extension investigating long term safety.
An Indian multi-centre, prospective, open-label, single-arm, non-interventional, post marketing surveillance study of Fiasp® to evaluate safety and effectiveness in patients with diabetes mellitus in routine clinical practice.
28431754DIA3018 (Pediatric type 2 study on Canagliflozin)
A randomized, multicenter, Double-blind, parallel-group, Placebo-controlled study to investigate the efficacy and safety of Canagliflozin in children and adolescents (≥10 to <18) with type 2 diabetes mellitus.